SyntheMed Receives Endorsement, New Patent
REPEL-CV, a bioresorbable anti-adhesion barrier developed by biomaterials company SyntheMed, has received an endorsement from Kids with Heart.
feature2
Antidepressant Use Doubled In U.S. Over Past Decade
Antidepressant use in the U.S. nearly doubled between 1996 and 2005, according to a new report.
Purdue, Transcept Sign $145M Deal for Sleep Aid
Purdue Pharmaceutical Products and Transcept Pharmaceuticals have signed a $145 million agreement to commercialize the sleep aid Intermezzo in the U.S.
Burrill Report: Leading Malaria Drug Becoming Less Effective
Poor regulations and substandard use could be to blame for growing resistance to a leading anti-malaria drug, researchers say.
FDA Approves First Monthly Atypical Antipsychotic for Schizophrenia
The U.S. Food and Drug Administration has approved Janssen Pharmaceuticals’ Invega Sustenna for acute and maintenance treatment of schizophrenia.
Bioheart Gets the Go-Ahead for Clinical Trial of Heart Failure Therapy
Bioheart, a developer of cell-based therapies for cardiovascular diseases, has been granted FDA approval to proceed with a Phase I clinical trial for a potential congestive heart failure treatment.
DATATRAK Awarded Phase III Trial With Top 20 Pharma Company
DATATRAK International, a provider of technical support systems for clinical studies, has been awarded a Phase III clinical trial by the European division of a Global Top 20 pharmaceutical company.
Wireless Pacemakers Approved for Patient Use
With the U.S. approval of two new wireless devices from St. Jude Medical, pacemaker users may no longer have to go to the doctor for follow-up visits.
Biotech Industry Tops for Venture Capital Investors
A new report published by PricewaterhouseCoopers and the National Venture Capital Association found that life sciences companies garnered the most investment dollars out of any industry in the second quarter of 2009.
Human Genome’s Lupus Drug Surprises Analysts
Shares in Human Genome Sciences increased by 277 percent on Monday after the company announced that their lupus drug Benlysta succeeded in a Phase III clinical trial.